Patents by Inventor Albert L. Rubin

Albert L. Rubin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods useful in endotoxin based therapy
    Patent number: 5506218
    Abstract: Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering phospholipid containing compositions to the subject. The compositions are protein and peptide free, and may contain triglycerides, or other polar or neutral lipids.
    Type: Grant
    Filed: August 10, 1994
    Date of Patent: April 9, 1996
    Assignee: The Rogosin Institute
    Inventors: Thomas S. Parker, Daniel M. Levine, Albert L. Rubin, Bruce R. Gordon, Stuart D. Saal
  • Methods useful in endotoxin prophylaxis and therapy
    Patent number: 5344822
    Abstract: Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering a lipid into which the endotoxin of concern is associated, preferably together with a peptide which is not an apolipoprotein. Preferably, the two components are administered in the form of a reconstituted particle, although this is by no means required.
    Type: Grant
    Filed: August 12, 1992
    Date of Patent: September 6, 1994
    Assignee: The Rogosin Institute
    Inventors: Daniel M. Levine, Thomas S. Parker, Albert L. Rubin
  • Reconstituted HDL particles and uses thereof
    Patent number: 5128318
    Abstract: A reconstituted high density lipoprotein containing particle is disclosed. The particle is useful in removing excess lipid soluble material from a subject to which it is administered, as well as in delivery of lipid soluble pharmaceuticals to subjects or patients.
    Type: Grant
    Filed: October 27, 1988
    Date of Patent: July 7, 1992
    Assignee: The Rogosin Institute
    Inventors: Daniel M. Levine, Sanford R. Simon, Bruce R. Gordon, Thomas S. Parker, Stuart D. Saal, Albert L. Rubin
  • Method for manufacturing pyrogen-free collagen gels useful as contact lenses
    Patent number: 4687518
    Abstract: Pyrogen-free collagen useful for manufacturing soft contact lenses is made by performing all manufacturing process steps under aseptic conditions.
    Type: Grant
    Filed: November 6, 1985
    Date of Patent: August 18, 1987
    Assignee: Optical Corp.
    Inventors: Teruo Miyata, Albert L. Rubin
  • Chemically-modified fiber collagen hemostatic agents
    Patent number: 4271070
    Abstract: Chemically-modified quaternary-structured fiber collagens of minimum molecular length, diameter and periodicity, and containing a relatively high positive electrostatic charge are claimed as hemostatic agents. Specific examples are guanidinated, esterified, and guanidinated-esterified collagen fibers of the type described.
    Type: Grant
    Filed: May 5, 1980
    Date of Patent: June 2, 1981
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Teruo Miyata, Albert L. Rubin, Kurt H. Stenzel
  • Fiber collagen contact lens
    Patent number: 4268131
    Abstract: Soft contact lenses are made from purified fiber collagen and mixtures of such fiber with purified solubilized collagen.
    Type: Grant
    Filed: April 11, 1979
    Date of Patent: May 19, 1981
    Assignee: Opticol Corporation
    Inventors: Teruo Miyata, Albert L. Rubin, Kurt H. Stenzel, Michael W. Dunn
  • Collagen soft contact lens
    Patent number: 4223984
    Abstract: Soft contact lenses are made from solubilized, defatted, transparent, cross-linked collagen, and/or chemically-modified collagen.
    Type: Grant
    Filed: April 4, 1979
    Date of Patent: September 23, 1980
    Assignee: Opticol Corporation
    Inventors: Teruo Miyata, Albert L. Rubin, Michael W. Dunn, Kurt H. Stenzel
  • Chemically and enzymatically modified collagen hemostatic agent
    Patent number: 4215200
    Abstract: Polymers of quaternary-structured collagen of minimum length, diameter and periodicity, and containing a relatively high positive electrostatic charge are claimed as hemostatic agents. Specific examples are guanidnated polymers of the type described, esterified polymers, and esterified-guanidinated polymers.
    Type: Grant
    Filed: October 2, 1978
    Date of Patent: July 29, 1980
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Teruo Miyata, Kurt H. Stenzel, Albert L. Rubin
  • Collagen drug delivery device
    Patent number: 4164559
    Abstract: Chemically-modified collagen membrane prepared at physiologic pH and soluble thereat provides a carrier for ophthalmic medication leaving no removable material after drug release.
    Type: Grant
    Filed: September 21, 1977
    Date of Patent: August 14, 1979
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Teruo Miyata, Albert L. Rubin, Kurt H. Stenzel, Michael W. Dunn